TABLE 3.
Pathological Findings
| Total n = 274 | FLX n = 183 | GNP n = 91 | P | |
|---|---|---|---|---|
| Frozen margin, n = 244 | ||||
| Positive | 24 (9.9) | 22 (13.5) | 2 (2.5) | |
| Negative | 208 (85.2) | 131 (80.4) | 77 (95) | 0.008* |
| No margin | 12 (4.9) | 10 (6.1) | 2 (2.5) | |
| Second frozen margin (positive), n = 246 | ||||
| Positive | 16 (6.5) | 15 (9.4) | 1 (1.2) | |
| Negative | 3 (1.2) | 2 (1.3) | 1 (1.2) | 0.045* |
| No margin | 227 (92.3) | 143 (89.4) | 84 (97.6) | |
| Surgical margins, n = 211 | ||||
| R0 | 174 (82.5) | 111 (82.8) | 63 (81.8) | 0.853 |
| R1/R2 | 37 (17.5) | 23 (17.2) | 14 (18.2) | |
| Margin positivity (site) | ||||
| Pancreatic neck, n = 262 | 23 (8.8) | 14 (8) | 9 (10.3) | 0.643 |
| SMA, n = 196 | 11 (5.6) | 4 (3) | 7 (10.9) | 0.042* |
| Bile duct, n = 235 | 3 (1.3) | 1 (0.6) | 2 (2.5) | 0.274 |
| Tumor size, cm, median (IQR) | 2.5 (1.9–3.3) | 2.5 (2–3.5) | 2.5 (1.5–3.2) | 0.016* |
| pT stage, n = 261 | ||||
| pT0 | 3 (1.1) | 2 (1.2) | 1 (1.1) | |
| pT1 | 44 (16.9) | 19 (21.6) | 25 (14.5) | |
| pT2 | 77 (29.5) | 52 (30.1) | 25 (28.4) | 0.651 |
| pT3 | 135 (51.7) | 93 (53.8) | 42 (47.7) | |
| pT4 | 2 (0.8) | 1 (0.6) | 1 (1.1) | |
| pN stage, n = 268 | ||||
| pN0 | 128 (47.8) | 87 (48.9) | 41 (45.6) | 0.789 |
| pN1 | 117 (43.7) | 77 (43.3) | 40 (44.4) | |
| LNs examined, median (IQR) | 19 (14–26) | 20 (15–26) | 18 (14–23) | 0.031* |
| Positive LNs, median (IQR) | 1 (0–2) | 1 (0–2) | 1 (0–3) | 0.294 |
| Grade, n = 239 | ||||
| Well differentiated | 32 (13.4) | 19 (12.1) | 13 (16) | |
| Moderately differentiated | 137 (57.4) | 91 (57.6) | 46 (56.8) | 0.772 |
| Poorly differentiated | 69 (28.8) | 47 (29.7) | 22 (27.2) | |
| Undifferentiated | 1 (0.4) | 1 (0.6) | 0 | |
| Lymphovascular invasion, n = 255 | 118 (46.3) | 83 (48.8) | 35 (41.2) | 0.287 |
| Perineural invasion, n = 259 | 187 (72.2) | 123 (71.1) | 64 (74.4) | 0.659 |
| Tumor response grade, n = 220 | ||||
| pCR | 13 (6) | 9 (5.8) | 4 (6.3) | |
| pPR | 124 (56.3) | 88 (56.4) | 36 (56.2) | 0.992 |
| pLR | 83 (37.7) | 59 (37.8) | 24 (37.5) |
FLX indicates FOLFIRINOX; GNP, gemcitabine/nab-paclitaxel; IQR, interquartile range; LN, lymph node; pCR, complete pathological response; pLR, none/limited pathological response; pPR, partial pathological response; SMA, superior mesenteric artery.
*
Statistically significant.